NCT07200583 2025-11-18
PAIA-Haplo
Fujian Medical University
Completed
Clinical Trials
10 trialsNCT02352558 2023-11-14
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT01860170 2023-06-02
Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
Corewell Health West
Phase 1/2 Completed
NCT00439556 2019-09-10
Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01460420 2017-07-06
EMN-alloRIC
European Myeloma Network B.V.
Phase 1/2 Completed
NCT00440479 2015-04-16
ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.
Janssen-Cilag B.V.
Completed
NCT00750815 2014-01-20
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00440765 2014-01-14
VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
Janssen-Cilag B.V.
Completed
NCT00068315 2013-09-30
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00369226 2013-07-25
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Dana-Farber Cancer Institute
Phase 1/2 Completed